COVID-19 and thrombosis: Prophylaxis and management COVID-19 ve tromboz: Profilaksi ve yönetimi
Tuberkuloz ve Toraks, cilt.69, sa.2, ss.269-278, 2021 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 69 Sayı: 2
- Basım Tarihi: 2021
- Doi Numarası: 10.5578/tt.20219818
- Dergi Adı: Tuberkuloz ve Toraks
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.269-278
- Anahtar Kelimeler: Anticoagulants, COVID-19, heparin, low-molecular-weight, thrombosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a pandemic on March 11, 2020. The disease has a wide spectrum ranging from asymptomatic or mild disease to ARDS and death. There have been over 83.9 million cases with 1.8 million deaths worldwide. COVIDassociated coagulopathy appears to be an entity responsible for deaths. Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism. Low molecular weight heparin such as enoxaparin is often recommended. However, there is still no consensus regarding the treatment dose and duration. The purpose of this review was to observe the pathogenesis of thromboembolic events in COVID-19, current thromboprophylaxis regimens, treatment dosage and duration with guidelines of international scientific institutions.